Oramed Pharmaceuticals (ORMP) Shares Outstanding (Weighted Average) (2011 - 2026)

Oramed Pharmaceuticals has reported Shares Outstanding (Weighted Average) for 16 years, with the latest figure at $40.8 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 1.1% year-over-year to $40.8 million; the trailing twelve-month figure through Mar 2026 stood at $40.8 million (down 1.1% YoY), and the FY2025 full-year result was $41.4 million, up 1.35% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $40.8 million, down from $41.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $41.8 million in Q3 2025, with the low at $38.7 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $40.4 million across 5 years, with a median of $40.8 million in 2026.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) advanced 3.85% — and 2026, when it retreated 1.1%.
• Oramed Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $39.0 million in 2022, then advanced by 3.38% to $40.3 million in 2023, then advanced by 1.33% to $40.9 million in 2024, then grew by 1.35% to $41.4 million in 2025, then dropped by 1.52% to $40.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $40.8 million (Q1 2026), $41.4 million (Q4 2025), and $41.8 million (Q3 2025), per Business Quant data.